| Literature DB >> 32564308 |
Shannon Galyean1, Dhanashree Sawant2, Andrew C Shin2.
Abstract
BACKGROUND: Bariatric surgery can effectively treat morbid obesity; however, micronutrient deficiencies are common despite recommendations for high-dose supplements. Genetic predisposition to deficiencies underscores necessary identification of high-risk candidates. Personalized nutrition (PN) can be a tool to manage these deficiencies.Entities:
Keywords: Deficiency; Gene; Gene expression; Nutrients; Obesity; Polymorphism; Supplementation
Mesh:
Substances:
Year: 2020 PMID: 32564308 PMCID: PMC7378102 DOI: 10.1007/s11695-020-04762-3
Source DB: PubMed Journal: Obes Surg ISSN: 0960-8923 Impact factor: 4.129
Relevance of genetic variants associated with micronutrient metabolism
| Micronutrients | Genes identified with micronutrients | Relevance in micronutrient status | Reference |
|---|---|---|---|
| Vitamin D | 1. GC 2. CYP2R1 3. DHCR7 4. CYP24A 5. VDR | 1. GC gene encodes Vitamin D Binding Protein (DBP) which is a glycosylated alpha-globulin that transports vitamin D metabolites from gut and skin to target end-organs. 2. CYP2R1 gene encodes 25-hydroxylase, which converts Vitamin D to 25(OH)D. 3. DHCR7 gene provides instructions for making 7-dehydrocholesterol reductase, an enzyme involved in the final step of cholesterol production. 4. CYP24A gene provides instructions for making 24-hydroxylase, an enzyme that controls the amount of active vitamin D in the body. 5. VDR gene provides instructions for making vitamin D receptor (VDR) protein, which allows the body to respond appropriately to vitamin D >A variation in these genes may impact body vitamin D levels. | [ |
| B12 | 1. FUT2 2. CUBN 3. TCN1 4. MTRR 5. TCN2 6. MTR 7. MMAA 8. MMACHC | 1. FUT2 gene encodes for fucosyltransferase 2 gene and is involved in Vit B12 absorption and transport. 2. CUBN gene provides instructions for making cubilin protein which is involved in the uptake of vitamin B12. 3. TCN1 gene encodes B12-binding protein family which facilitates the transport of cobalamin into cells. 4. MTRR gene is responsible for maintaining adequate levels of activated vitamin B12, which maintains methionine synthase enzyme in its active state. 5. TCN2 provides instructions for making transcobalamin. 6. MTR gene provides instructions for making methionine synthase enzyme which needs B12 and is involved in the formation of the amino acid methionine 7. The protein encoded by MMAA gene is involved in the translocation of cobalamin into the mitochondrion. 8. It is postulated that the protein encoded by MMACHC gene may have a role in the binding and intracellular trafficking of cobalamin. >SNP related to these genes can lead to insufficient B12 levels in the body. | [ |
| Folic acid | 1.MTHFR | 1. MTHFR gene produces Methylenetetrahydrofolate reductase (MTHFR) which is a vital enzyme for the folate pathway. >SNP related to this gene may be an important marker to identify people at risk for lower plasma folate concentrations, changes in folate form distribution, and elevated plasma homocysteine concentrations. | [ |
| Thiamine | 1.SLC19A2 2. SLC19A3 3. SLC35F3 | SLC19A2, SLC19A3 and SLC35F3 genes code for thiamine transporter protein which allow thiamine to move into the cells. >Mutations in these gene can cause thiamine deficiency leading to thiamine responsive megaloblastic anemia. | [ |
| Iron | 1.TMPRSS6 2.TFR2 3.TF 4. HFE | 1. TMPRSS6 gene codes for the protein matriptase-2 which helps in regulation of iron balance. 2. TFR2 gene codes for TFR2 protein which facilitates entry of iron into the cells. 3. TF gene codes for protein transferrin which is a transport protein for iron in the body. 4. HFE gene provides instruction for production of HFE protein which determines iron absorption from diet and iron release from body stores. >A variation in these genes together has an impact on the risk of insufficient iron levels in the body. | [ |
Supplementation trials according micronutrient defect
| Reference | Micronutrient | Defective or mutated gene | Dosage and monitoring | No. of patients | Summary |
|---|---|---|---|---|---|
| [ | Thiamine | SLC19A2 | 75 mg thiamine/day | Case study of 1 female patient | Patients with this defect present with diabetes mellitus, megaloblastic anemia, and sensorineural deafness. Thiamine supplementation improved blood glucose and insulin requirements decreased. |
| [ | SLC19A3 | 100 mg thiamine 2×/day along with 10 mg biotin 2×/day for 5 months | Case study of 1 female patient | This genetic defect causes ophthalmoplegia, ataxia and confusion. Oral biotin and thiamine improved the symptoms dramatically the next day. | |
| [ | TPK1 | 500 mg thiamine/day | 2 patients with homozygous | Early thiamine supplementation prevented encephalopathic episodes and improved developmental progression. Evidence suggests that thiamine supplementation may rescue TPK enzyme activity. | |
| [ | Vitamin D | GC | 50,000 IU vitamin D3 per week for 8 weeks, followed by daily maintenance of 1000 IU vitamin D3 for 4 months | 234 participants with vitamin D deficiency | Carriers of GC mutation showed the lowest baseline 25(OH)D levels and lowest response to vitamin D supplementation. Mutations in GC gene can predict response to vitamin D supplementation. |
| [ | CYP2R1, CYP24A1, VDR | Vitamin D3 (1000 IU/day) and/or calcium carbonate (1200 mg/day elemental calcium) | 1787 healthy participants | The increase in [25(OH)D] attributable to vitamin D3 supplementation may vary according to common genetic differences in CYP2R1, CYP24A1, and VDR genes. | |
| [ | Folic acid (FA) | MTHFR | Each treatment taken once daily for 8 weeks. 1. Enalapril only (10 mg, control group) 2. Enalapril-FA tablet (10 mg enalapril combined with 0.4 mg of FA) 3. Enalapril-FA tablet (10 mg enalapril combined with 0.8 mg of FA) | 480 subjects with mild or moderate essential hypertension | MTHFR mutation can affect homocysteine concentration at baseline and post-FA treatment as well as can modify therapeutic responses to various dosages of FA supplementation. |
| [ | MTHFR 677C → T genotype | 3 random dietary interventions (4 months each): 1. Exclusion diet (avoidance of FA–fortified foods) 2. Folate-rich diet (folate-rich foods to achieve 400 mcg folate/d) 3. Supplement (exclusion diet plus a folate supplement of 400 mcg/day) | 126 healthy subjects (42 TT, 42 CT, and 42 CC genotypes) | The TT homozygotes tended to have low plasma folate and high plasma homocysteine levels. Folate intervention on plasma folate was observed across genotypes. However, the TT homozygotes required higher supplement intervention to achieve similar effects observed in other genotypes suggesting a need for supplementation with at least 400–600 mcg/day for individuals with the TT genotype. | |
| [ | Vitamin B12 | MTHFR 677C→T genotype | One vitamin tablet consisting of 2 mg of folic acid, 25 mg vitamin B6, and 400 μg of vitamin B12 daily for 6 months | 52 patients with migraine with aura. | Vitamin supplementation lowered homocysteine and reduced migraine disability in a subgroup of patients. In this patient group the treatment effect on both homocysteine levels and migraine disability was associated with MTHFR C677T genotype; carriers of the C allele experienced a greater response compared to TT genotypes concluding that TT genotypes require a larger dosage of vitamins to exhibit the same effect as C alleles. |
| [ | Iron | HFE, TMPRSS6, TF | Iron supplementation with autrin capsules (ferrous fumarate; 98.6 mg elemental iron) once a day for 20 weeks from the time of diagnosis | 181 pregnant women with anemia | The HFE variant had a positive effect with significant improvement in hemoglobin, iron and ferritin. This shows an association of genetic variants and iron absorption and thus response to treatment. The TMPRSS6 mutation was significantly associated with higher serum iron and hemoglobin. The presence of variants in STEAP3, TMPRSS6, SLC11A2, SLC40A1, HAMP and TF genes indicate a probable genetic association with iron status. |
| [ | TMPRSS6 | Intravenous iron gluconate (1.3 mg/kg/day) for 5 days as first course and same dose was repeated after 5 months Followed by different supplementation therapy in which the patient received liposomal oral iron at a dose of 10 mg/day for 3 months | Case study of 1 female patient | A comprehensive assessment that includes sequence analysis of TMPRSS6 can help to confirm the genotype-phenotype association of genes involved in iron metabolism and may also be useful for predicting the patient’s response to iron treatment. |